Daval International , a UK private company, says that the Medicines and Healthcare products Regulatory Agency (MHRA) and the independent review board have approved a London-based Phase IIb trial of Aimspro, its hyperimmune caprine serum derivative.
This double-blind, cross-over study will seek to detect a beneficial effect on bladder function in patients with secondary progressive multiple sclerosis, following open-label observations over several years in a number of informed consent, compassionate-use basis patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze